ATOS - Atossa Genetics Inc Stock Price, Fair Value and News

1.50USD+0.01 (+0.67%)Market Closed

Market Summary

USD1.50+0.01

Market Closed

0.67%

ATOS Alerts

1 major insider buys recently.

ATOS Stock Price

View Fullscreen

ATOS RSI Chart

ATOS Valuation

Market Cap

188.0M

Price/Earnings (Trailing)

-6.25

Price/Sales (Trailing)

2.9K

EV/EBITDA

-3.31

Price/Free Cashflow

-8.99

ATOS Price/Sales (Trailing)

ATOS Profitability

Operating Margin

1752.83%

EBT Margin

-35556.13%

Return on Equity

-33.06%

Return on Assets

-31.27%

Free Cashflow Yield

-11.13%

ATOS Fundamentals

ATOS Revenue

Revenue (TTM)

84.6K

ATOS Earnings

Earnings (TTM)

-30.1M

Earnings Growth (Yr)

-3.51%

Earnings Growth (Qtr)

-24.48%

Breaking Down ATOS Revenue

Last 7 days

11.1%

Last 30 days

-20.6%

Last 90 days

87.5%

Trailing 12 Months

136.3%

How does ATOS drawdown profile look like?

ATOS Financial Health

Current Ratio

17.61

ATOS Investor Care

Buy Backs (1Y)

1.04%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2015	0	0	0	0
2014	474.0K	157.8K	84.6K	0
2013	609.8K	712.8K	683.8K	632.6K
2012	0	0	0	481.8K
2011	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Atossa Genetics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 10, 2024	finn jonathan	bought	44,250	1.77	25,000	-
Nov 15, 2023	weaver gregory l	sold	-32,500	0.65	-50,000	former evp, cfo, & director
Jun 20, 2023	weaver gregory l	bought	48,500	0.97	50,000	evp & cfo
Jul 02, 2021	weaver gregory l	acquired	365,337	2.2198	164,581	-
Jul 02, 2021	weaver gregory l	sold	-599,833	5.58	-107,497	-
Jul 02, 2021	weaver gregory l	sold (taxes)	-365,338	6.4	-57,084	-

Which funds bought or sold ATOS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	REGIONS FINANCIAL CORP	unchanged	-	27,600	54,000	-%
Apr 22, 2024	PFG Investments, LLC	new	-	42,570	42,570	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	unchanged	-	9,950	19,467	-%
Apr 15, 2024	St. Johns Investment Management Company, LLC	unchanged	-	1,426	2,790	-%
Apr 05, 2024	NBC SECURITIES, INC.	new	-	1,000	1,000	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	814,466	4,994,640	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-59,000	-	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	unchanged	-	246	1,506	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	added	29.27	139,000	395,000	0.03%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-12,743	-	-%

Are Funds Buying or Selling ATOS?

Are funds buying ATOS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATOS

No. of Funds

ATOS Alerts

1 major insider buys recently.

Unveiling Atossa Genetics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	4.50%	5,697,536	SC 13G/A
Jul 08, 2022	blackrock inc.	2.8%	3,588,683	SC 13G
Feb 14, 2022	cvi investments, inc.	5.8%	7,762,500	SC 13G/A
Feb 09, 2022	vanguard group inc	5.51%	6,970,850	SC 13G
Feb 04, 2022	blackrock inc.	7.5%	9,539,593	SC 13G
Jan 13, 2022	empery asset management, lp	1.03%	1,312,500	SC 13G/A
Jan 15, 2021	cvi investments, inc.	-	3,800,000	SC 13G
Jan 15, 2021	intracoastal capital, llc	4.99%	3,749,923	SC 13G
Jan 15, 2021	cvi investments, inc.	-	2,304,289	SC 13G/A
Jan 14, 2021	empery asset management, lp	5.32%	3,800,000	SC 13G

Recent SEC filings of Atossa Genetics Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	4	Insider Trading
Apr 02, 2024	8-K/A	Current Report
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	3	Insider Trading
Mar 12, 2024	8-K	Current Report

Peers (Alternatives to Atossa Genetics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Atossa Genetics Inc News

Latest updates

Atossa Genetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2	2012Q1	2011Q4
Revenue	-100.0%	-	772,244	2,694,157	1,873,268	938,347	3,426	9,875	24,124	47,213	76,597	326,078	182,670	98,456	105,576	223,097	54,713	-
Cost Of Revenue	-646.4%	-1,712,327	313,406	-	-	-	-	-	-	30,957	25,938	222,160	66,464	5,760	9,000	17,788	3,197	-
Gross Profit	-392.4%	-1,341,871	458,838	-	-	2,713	3,426	9,875	24,124	-133,690	50,659	103,918	116,206	92,696	90,499	205,309	27,709	-
Interest Expenses	-	-	-	-	1,784	13,426	151	1,443	749	-	1.00	352	7.00	224	7,756	2,446	1,613	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.4%	96.00	102	108	116	124	127	134	137	141	143	146	141	43.00	11.00	10.00	12.00	14.00	17.00	19.00	21.00	12.00
Current Assets	-5.6%	92.00	98.00	106	111	118	123	133	137	141	143	146	141	43.00	11.00	10.00	12.00	14.00	16.00	18.00	21.00	12.00
Cash Equivalents	-5.9%	88.00	94.00	99.00	104	111	117	126	131	136	140	142	138	40.00	9.00	7.00	9.00	13.00	15.00	17.00	20.00	10.00
Net PPE	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	52.0%	5.00	3.00	3.00	3.00	6.00	3.00	4.00	2.00	3.00	2.00	-	-	16.00	2.00	2.00	1.00	1.00	2.00	1.00	2.00	3.00
Current Liabilities	52.0%	5.00	3.00	3.00	3.00	6.00	3.00	4.00	2.00	3.00	2.00	2.00	1.00	16.00	2.00	2.00	1.00	1.00	2.00	1.00	1.00	3.00
Shareholder's Equity	-7.4%	91.00	98.00	105	113	118	124	130	135	138	141	144	140	27.00	10.00	8.00	11.00	13.00	15.00	18.00	19.00	9.00
Retained Earnings	-4.3%	-186	-178	-172	-162	-156	-148	-140	-134	-129	-124	-119	-112	-111	-104	-100	-97.02	-94.07	-91.45	-88.17	-80.90	-76.83
Additional Paid-In Capital	-100.0%	-	255	254	252	251	249	248	246	244	242	240	229	130	112	107	106	105	104	103	98.00	82.00
Shares Outstanding	0.0%	125	125	127	127	127	127	127	127	127	127	107	93.00	48.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	138	-	-	-	796	-	-	-	35.00	-	-	-	23.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-42.4%	-5,530	-3,883	-4,465	-7,022	-4,523	-5,410	-5,949	-4,878	-3,665	-3,062	-5,337	-4,408	-3,432	-2,678	-2,229	-3,229	-2,708	-1,768	-2,502	-2,148	-2,443
Cashflow From Investing	100.0%	-	-1.00	-13.00	-	-2,008	-2,706	-	-13.00	-	-9.00	-	-	367*	-2.76	-	-	-	-	-	-	-56.46
Cashflow From Financing	100.0%	-	-1,475	-	-	-	-	-	-	1.00	679	10,196	102,428	33,880	4,324	-	-	-	-	-	11,337	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

ATOS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 17,334,000	$ 15,083,000
General and administrative	14,043,000	12,608,000
Total operating expenses	31,377,000	27,691,000
Operating loss	(31,377,000)	(27,691,000)
Impairment charge on investment in equity securities	(2,990,000)	0
Interest income	4,343,000	877,000
Other expense, net	(70,000)	(146,000)
Loss before income taxes	(30,094,000)	(26,960,000)
Income taxes benefit	0	0
Net loss	$ (30,094,000)	$ (26,960,000)
Net loss per share of common stock - basic (in dollars per share)	$ (0.24)	$ (0.21)
Net loss per share of common stock - diluted (in dollars per share)	$ (0.24)	$ (0.21)
Weighted average shares outstanding used to compute net loss per share- basic (in shares)	126,081,602	126,624,110
Weighted average shares outstanding used to compute net loss per share - diluted (in shares)	126,081,602	126,624,110

ATOS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 88,460	$ 110,890
Restricted cash	110	110
Prepaid materials	1,487	5,247
Prepaid expenses and other current assets	2,162	1,207
Research and development tax rebate receivable	0	743
Total current assets	92,219	118,197
Investment in equity securities	1,710	4,700
Other assets	2,323	635
Total Assets	96,252	123,532
Current liabilities
Accounts payable	806	2,965
Accrued expenses	973	1,059
Payroll liabilities	1,654	1,525
Other current liabilities	1,803	19
Total current liabilities	5,236	5,568
Total Liabilities	5,236	5,568
Commitments and contingencies (Note 13)
Stockholders' equity
Convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock - $0.18 par value; 175,000,000 shares authorized; 125,304,064 and 126,624,110 shares issued and outstanding as of December 31, 2023 and 2022, respectively	22,792	22,792
Additional paid-in capital	255,987	251,366
Treasury stock, at cost; 1,320,046 and 0 shares of common stock at December 31, 2023 and 2022, respectively	(1,475)	0
Accumulated deficit	(186,288)	(156,194)
Total Stockholders' Equity	91,016	117,964
Total Liabilities and Stockholders' Equity	$ 96,252	$ 123,532

About Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

CEO	Dr. Steven C. Quay FCAP, M.D., Ph.D.
WEBSITE	https://atossatherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	11

Atossa Genetics Inc Frequently Asked Questions

What is the ticker symbol for Atossa Genetics Inc? What does ATOS stand for in stocks?

ATOS is the stock ticker symbol of Atossa Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atossa Genetics Inc (ATOS)?

As of Wed Apr 24 2024, market cap of Atossa Genetics Inc is 187.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATOS stock?

You can check ATOS's fair value in chart for subscribers.

What is the fair value of ATOS stock?

You can check ATOS's fair value in chart for subscribers. The fair value of Atossa Genetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Atossa Genetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Atossa Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether ATOS is over valued or under valued. Whether Atossa Genetics Inc is cheap or expensive depends on the assumptions which impact Atossa Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATOS.

What is Atossa Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, ATOS's PE ratio (Price to Earnings) is -6.25 and Price to Sales (PS) ratio is 2.95 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATOS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Atossa Genetics Inc's stock?

In the past 10 years, Atossa Genetics Inc has provided -0.395 (multiply by 100 for percentage) rate of return.